Ilomedin (Iloprost Trometamol)

Iloprost Trometamol is a selective agonist of the prostacyclin (IP) receptor. Activation of this receptor increases cyclic AMP within vascular smooth‑muscle cells, causing vasodilation, inhibiting platelet aggregation, and exerting antiproliferative effects that together improve blood flow in the pulmonary circulation and peripheral microvasculature.

The dosing regimen for Ilomedin is individualized. The prescribing clinician determines the infusion rate, concentration, and duration based on the patient’s clinical status, response, and tolerance, following established guidelines for pulmonary arterial hypertension or digital ulcer therapy.

The pregnancy category for Ilomedin is unknown. Because it may affect vascular tone and platelet function, it should only be used during pregnancy or lactation if the potential benefits justify the potential risks, and after a thorough risk‑benefit assessment by the treating physician.

To order Ilomedin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and assistance with import documentation.

Ilomedin belongs to the prostacyclin analog class, offering potent vasodilation and antiplatelet effects via IP‑receptor activation. Compared with endothelin receptor antagonists or phosphodiesterase‑5 inhibitors, it provides a direct prostacyclin pathway, which can be advantageous in patients who do not respond adequately to oral agents, though it requires intravenous administration.

Ilomedin should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the solution. Keep the product in its original packaging until use, and discard any solution that appears discolored or contains particles.

Ilomedin is supplied as a sterile solution for intravenous infusion. It is administered through a controlled infusion pump, typically over a period of 15‑30 minutes, with the infusion rate adjusted according to the patient’s hemodynamic response and tolerability, under close medical supervision.

Serious risks include severe hypotension, pulmonary edema, significant bleeding due to antiplatelet activity, thrombocytopenia, arrhythmias, and rare anaphylactic reactions. Patients should be monitored closely for signs of these events, and infusion should be halted immediately if they occur.

Ilomedin is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, in those with severe uncontrolled hypotension, and in individuals who have experienced recent myocardial infarction or severe bleeding disorders without appropriate medical oversight.